About Akero
Our dedicated team is laser-focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Andrew Cheng, MD, PhD
President & Chief Executive Officer
AKR-001
Our multi-modal drug, AKR-001, mimics FGF21 to confront the many facets of NASH. We recently announced topline results of our ongoing BALANCED trial, which showed statistically significant reductions in liver fat for all three tested doses of AKR-001 compared to placebo.
Management
Johnathan Young, PhD, JD
Chief Operating Officer & Co-Founder
Tim Rolph, DPhil
Chief Science Officer & Co-Founder
William White
Chief Financial Officer & Head of Corporate Development
Kitty Yale
Chief Development Officer
Board of Directors
Careers
We invite qualified applicants who share our commitment to send your resume and cover letter to careers@akerotx.com.
